Mallinckrodt PLC (NYSE:MNK) – Stock analysts at Jefferies Financial Group raised their FY2018 EPS estimates for shares of Mallinckrodt in a research report issued to clients and investors on Tuesday, November 6th. Jefferies Financial Group analyst A. Petrone now expects that the company will post earnings per share of $7.10 for the year, up from their previous forecast of $6.80. Jefferies Financial Group also issued estimates for Mallinckrodt’s Q4 2018 earnings at $1.91 EPS, Q1 2019 earnings at $1.63 EPS, Q2 2019 earnings at $1.99 EPS, Q3 2019 earnings at $2.04 EPS, Q4 2019 earnings at $1.95 EPS, FY2019 earnings at $7.60 EPS and FY2020 earnings at $8.25 EPS.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $2.10 EPS for the quarter, beating the consensus estimate of $1.79 by $0.31. The firm had revenue of $640.00 million during the quarter, compared to analysts’ expectations of $634.38 million. Mallinckrodt had a return on equity of 9.60% and a net margin of 65.24%. The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.97 EPS.
MNK has been the subject of several other research reports. Canaccord Genuity reaffirmed a “hold” rating and issued a $22.00 price target on shares of Mallinckrodt in a report on Monday, August 13th. Berenberg Bank started coverage on Mallinckrodt in a report on Friday, September 14th. They issued a “sell” rating and a $25.00 price target for the company. Mizuho reaffirmed a “hold” rating and issued a $27.00 price target on shares of Mallinckrodt in a report on Tuesday. Zacks Investment Research cut Mallinckrodt from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Wells Fargo & Co reaffirmed a “hold” rating on shares of Mallinckrodt in a report on Wednesday, August 22nd. Four research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have given a buy rating to the company’s stock. Mallinckrodt currently has a consensus rating of “Hold” and an average target price of $32.53.
Mallinckrodt stock opened at $30.89 on Thursday. The company has a quick ratio of 2.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 4.12, a PEG ratio of 0.40 and a beta of 1.71. Mallinckrodt has a 12 month low of $11.65 and a 12 month high of $36.65.
Several institutional investors and hedge funds have recently modified their holdings of the company. Vident Investment Advisory LLC raised its holdings in shares of Mallinckrodt by 1.7% in the 2nd quarter. Vident Investment Advisory LLC now owns 166,782 shares of the company’s stock worth $3,112,000 after buying an additional 2,807 shares in the last quarter. American International Group Inc. raised its holdings in shares of Mallinckrodt by 1.3% in the 3rd quarter. American International Group Inc. now owns 222,252 shares of the company’s stock worth $6,514,000 after buying an additional 2,951 shares in the last quarter. United Services Automobile Association raised its holdings in shares of Mallinckrodt by 18.4% in the 2nd quarter. United Services Automobile Association now owns 19,432 shares of the company’s stock worth $363,000 after buying an additional 3,026 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in shares of Mallinckrodt by 46.7% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 15,238 shares of the company’s stock worth $284,000 after buying an additional 4,853 shares in the last quarter. Finally, Meeder Asset Management Inc. raised its holdings in shares of Mallinckrodt by 13.1% in the 3rd quarter. Meeder Asset Management Inc. now owns 43,634 shares of the company’s stock worth $1,278,000 after buying an additional 5,039 shares in the last quarter.
Mallinckrodt Company Profile
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
Further Reading: What are no-load funds?
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.